Oragenics (OGEN) AI Stock Analysis

• Market Cap: $3.53M
• Dividend Yield: N/A
• Average Volume (3M): 415.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.13
• Revenue Growth: -100.00%
• EPS Growth: 76.55%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -1.85
• Shares Outstanding: 715,843
• 10 Day Avg. Volume: 1,212,383
• 30 Day Avg. Volume: 415,188
• PEG Ratio: 0.03
• Price to Book (P/B): 1.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.70
• Enterprise Value/Market Cap: 1.37
• Enterprise Value/Revenue: 0.78
• Enterprise Value/Gross Profit: -5.32
• Enterprise Value/Ebitda: -0.08
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 29 Underperform
• Price Target: ―

Oragenics exhibits significant financial distress, with ongoing unprofitability, negative equity, and cash flow issues, contributing to a low financial performance score. The technical indicators reflect a weak stock momentum, further exacerbating the negative outlook. Valuation metrics are unfavorable due to negative earnings and lack of dividends, highlighting the challenges facing the company. Overall, the stock's fundamental and technical weaknesses are significant, resulting in a low overall score.

Oragenics Business Overview & Revenue Model

Company Description

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

How the Company Makes Money

Oragenics generates revenue primarily through research and development collaborations, grants, and potential milestone payments from strategic partnerships. The company focuses on advancing its product candidates through various stages of clinical trials, aiming to out-license or co-develop these products with larger pharmaceutical companies. Revenue is also derived from government and private funding initiatives that support the development of new antibiotics and treatments for infectious diseases. Long-term, Oragenics aims to commercialize its proprietary products, thereby generating revenue through product sales and royalties.

Oragenics Financial Statement Overview

Summary

Oragenics is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The company's financial position is fragile, with minimal revenues and ongoing reliance on financing activities to sustain operations. Improving operational efficiency and generating revenue growth are crucial to enhancing financial stability.

Income Statement

The company has experienced declining revenues over the years, with no revenues in 2024 and minimal revenues in previous years. Gross profit margins are negative, indicating cost inefficiencies or low sales volumes. The company has consistently reported negative EBIT and net income, reflecting ongoing unprofitability.

Balance Sheet

The balance sheet shows a negative stockholders' equity in 2024, indicating potential financial distress. The debt-to-equity ratio is not meaningful due to negative equity, though total liabilities have decreased over time. The company has maintained a high cash balance, which provides some liquidity despite ongoing losses.

Cash Flow

Operating cash flow has been negative, reflecting cash outflows from operations, though financing activities have provided some cash inflows. Free cash flow is consistently negative, which underscores the challenges in generating sufficient cash to cover operating and potential capital expenditures.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.14M	0.00	37.65K	131.52K	86.99K	0.00
	Gross Profit
-907.00K	0.00	-27.39K	86.85K	45.75K	-51.70K
	EBIT
-10.12M	-10.56M	-20.91M	-14.42M	-15.77M	-26.64M
	EBITDA
-10.11M	-10.56M	-20.88M	-14.23M	-15.65M	-26.37M
	Net Income Common Stockholders
-10.33M	-10.57M	-20.66M	-14.29M	-15.71M	-26.43M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.42M	864.84K	3.48M	11.43M	27.27M	17.64M
	Total Assets
3.87M	1.47M	4.97M	14.76M	28.23M	18.68M
	Total Debt
2.55M	328.53K	322.51K	624.53K	797.21K	898.92K
	Net Debt
-866.69K	-536.31K	-3.16M	-10.80M	-26.47M	-16.74M
	Total Liabilities
3.73M	1.68M	1.80M	1.75M	1.74M	1.84M
	Stockholders Equity
137.69K	-211.88K	3.17M	13.01M	26.49M	16.84M
Cash Flow		Free Cash Flow
-7.65M	-8.60M	-7.29M	-15.36M	-13.51M	-16.95M
	Operating Cash Flow
-7.65M	-8.60M	-7.29M	-15.23M	-13.47M	-16.95M
	Investing Cash Flow
0.00	0.00	-936.28K	-115.52K	-43.88K	0.00
	Financing Cash Flow
8.99M	5.98M	283.88K	-494.92K	23.14M	16.32M

Oragenics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OGEN, the sentiment is Negative. The current price of 4.63 is below the 20-day moving average (MA) of 4.90, below the 50-day MA of 5.31, and below the 200-day MA of 9.63, indicating a bearish trend. The MACD of -0.34 indicates Negative momentum. The RSI at 46.90 is Neutral, neither overbought nor oversold. The STOCH value of 24.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OGEN.

Oragenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
TOVX	45 Neutral	$4.34M	―	-100.01%	―	―	6.87%
JAGX	43 Neutral	$4.82M	―	-423.79%	―	13.93%	91.30%
XBIO	43 Neutral	$4.64M	―	-53.16%	―	-1.56%	5.01%
KZIA	31 Underperform	$10.66M	―	-3028.18%	―	―	19.58%
OGEN	29 Underperform	$3.53M	―	-748.05%	―	-100.00%	76.55%
KTTA		$6.32M	―	-82.81%	―	―	―

Oragenics Corporate Events

Oragenics Appoints Janet Huffman as CEO and CFO

On May 2, 2025, Oragenics, Inc. appointed Janet Huffman as the Chief Executive Officer, in addition to her role as Chief Financial Officer, under a new Executive Employment Agreement. This agreement outlines her compensation and severance terms, reflecting the company’s strategic leadership decisions. During the same day, the company’s Annual Meeting saw the re-election of directors and the approval of several proposals, including a reverse stock split and amendments to the company’s Articles of Incorporation and Equity Incentive Plan, indicating a focus on financial restructuring and growth.

Spark’s Take on OGEN Stock

According to Spark, TipRanks’ AI Analyst, OGEN is a Underperform.

Oragenics exhibits significant financial distress, with ongoing unprofitability, negative equity, and cash flow issues, contributing to a low financial performance score. The technical indicators reflect a weak stock momentum, further exacerbating the negative outlook. Valuation metrics are unfavorable due to negative earnings and lack of dividends, highlighting the challenges facing the company. Overall, the stock’s fundamental and technical weaknesses are significant, resulting in a low overall score.

To see Spark’s full report on OGEN stock, click here.